Research Article

The Effect of Cyclooxygenase Inhibition on Tendon-Bone Healing in an *In Vitro* Coculture Model

Tim Schwarting, Sebastian Pretzsch, Florian Debus, Steffen Ruchholtz, and Philipp Lechler

Department of Trauma, Hand and Reconstructive Surgery, University Hospital Marburg, 35043 Marburg, Germany

Correspondence should be addressed to Tim Schwarting; schwarti@med.uni-marburg.de

Received 24 December 2014; Accepted 16 April 2015

Academic Editor: Giuseppe Valacchi

Copyright © 2015 Tim Schwarting et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The effects of cyclooxygenase (COX) inhibition following the reconstruction of the anterior cruciate ligament remain unclear. We examined the effects of selective COX-2 and nonselective COX inhibition on bone-tendon integration in an *in vitro* model. We measured the dose-dependent effects of ibuprofen and parecoxib on the viability of lipopolysaccharide- (LPS-) stimulated and unstimulated mouse MC3T3-E1 and 3T3 cells, the influence on gene expression at the osteoblast, interface, and fibroblast regions measured by quantitative PCR, and cellular outgrowth assessed on histological sections. Ibuprofen led to a dose-dependent suppression of MC3T3 cell viability, while parecoxib reduced the viability of 3T3 cultures. Exposure to ibuprofen significantly suppressed expression of *Alpl* ($P < 0.01$), *Bglap* ($P < 0.001$), and *Runx2* ($P < 0.01$), and although parecoxib reduced expression of *Alpl* ($P < 0.001$), *Fmod* ($P < 0.001$), and *Runx2* ($P < 0.01$), the expression of *Bglap* was increased ($P < 0.01$). Microscopic analysis showed a reduction in cellular outgrowth in LPS-stimulated cultures following exposure to ibuprofen and parecoxib. Nonselective COX inhibition and the specific inhibition of COX-2 led to region-specific reductions in markers of calcification and cell viability. We suggest further *in vitro* and *in vivo* studies examining the biologic and biomechanical effects of selective and nonselective COX inhibition.

1. Introduction

Rupture of the anterior cruciate ligament (ACL) of the knee is a common injury with a growing incidence in professional and recreational sportspersons [1, 2], reflected in the growing number of surgical ACL reconstructions performed each year [3]. Knee stability is generally restored by arthroscopic ligament reconstruction based on the transplantation of free autologous tendon grafts [4]. Despite being a well-established and highly standardized surgical procedure, approximately 10% of patients require operative revision because of graft failure and persistent joint instability [5, 6]. The interface between tendon and bone is of critical importance for the successful osseous integration of the transplant into the femoral and tibial tunnels [7]. However, the clinical issue of bone-tendon integration is not limited to ACL reconstruction but is a rather prominent challenge to orthopaedic surgeons treating ligament and tendon injuries at many other anatomical structures, including rotator cuff lesions, rupture of the distal tendon of the biceps brachii and scapholunar ligament,

and the reconstruction of the medial patellofemoral ligament and lateral ankle joint stabilizers.

Conventional nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase- (COX-) 2 inhibitors are widely used following musculoskeletal trauma and as postoperative analgesics [8]. While the COX-1 isoform has been identified as a “housekeeper” enzyme that is constitutively expressed in almost all tissues, COX-2 is the product of an immediate-early gene that is rapidly inducible and tightly regulated [9]. The expression of COX-2 is highly restricted but is sharply upregulated during inflammatory processes. Both COX-1 and COX-2 are key enzymes in the synthesis of prostaglandins (PGs), which are important factors in bone metabolism and fracture healing [9]. Whereas COX-1 and COX-2 inhibitors reportedly impair bone formation, they both appear to enhance tendon-bone integration [8].

We examined the effects of nonselective COX inhibition and selective COX-2 inhibition on the interaction between osteoblasts and fibroblasts at the tendon-bone interface *in vitro*.

FIGURE 1: Illustration of the murine coculture model simulating bone-tendon integration *in vitro*.

2. Materials and Methods

If not otherwise specified, reagents were sourced from Sigma-Aldrich (Taufkirchen, Germany) and consumables from Sarstedt (Nümbrecht, Germany). All experiments were performed in triplicate.

2.1. Cell Lines. Cells from the murine MC3T3-E1 (pre-osteoblast) and 3T3 (fibroblast) lines (DSMZ, Braunschweig, Germany) were cultivated at 37°C in a humidified atmosphere of air and 5% CO₂ in Eagle's minimum essential medium, α modification (α MEM), and Dulbecco's modified essential medium (DMEM), respectively. Both media were supplemented with 10% fetal calf serum, 100 U/I penicillin, and 100 μ g/mL streptomycin. Experiments were performed at passages 7 to 9. MC3T3-E1 cells were adapted to DMEM 10 days before the initiation of the coculture.

2.2. MC3T3-E1/3T3 Coculture Model. A murine coculture model providing osteoblast, interface, and fibroblast regions as described by Wang and colleagues [10] was used to study the effects of COX inhibition on bone-tendon healing *in vitro*. A sterile agarose divider (1.2 cm width) was fixed to the base of a plastic cell culture dish, and 1×10^6 MC3T3-E1 cells were seeded on the left and 1×10^6 3T3 cells on the right of the divider (Figure 1). Cells allowed to become adherent over 10 min; then the cocultures were covered with fully supplemented DMEM with 10 μ g/mL ascorbic acid and 1 mM glycerol-2-phosphate. After 3 days under standard culture conditions, the agarose divider was removed. Cultures were stimulated with lipopolysaccharide (LPS) at a concentration of 1 ng/ μ L over 4 hours. Next, the supernatant was decanted and the nonselective COX inhibitor ibuprofen (Sigma-Aldrich, Steinheim, Germany) or the specific COX-2 inhibitor parecoxib (Pfizer, New York City, NY, USA) was added. At days 2 and 3, medium was carefully renewed. Medium was removed and cocultures were rinsed with ice-cold phosphate-buffered saline (PBS). A region-specific cell harvest was performed by applying 600 μ L Buffer RLT (lysis buffer in the RNeasy Kit, Qiagen, Hilden, Germany) to the upper border of the respective region, while the plate was held in a tilted position. For each area, lysed cells were removed

FIGURE 2: Stimulation of gene expression by recombinant BMP-2. Induction of target gene expression three days following the application of recombinant BMP-2 (500 ng) at the osteoblast region served as positive control. Gene expression was measured 3 days after the stimulation with BMP-2 (500 ng/mL) and normalized to housekeeping genes. *Alpl*: alkaline phosphatase; *Bglap*: bone gamma-carboxyglutamate protein; BMP-2: bone morphogenetic protein-2; *Runx2*: runt-related transcription factor 2. *P* values are provided as follows: * *P* < 0.05, ** *P* < 0.01, and *** *P* < 0.001.

from the plate using a cell scraper and collected in three separate tubes (osteoblast, interface, and fibroblast regions). Lysates were stored at -80°C. Cultures treated with dimethyl sulfoxide (DMSO, 520 μ M) and NaCl (36.02 μ M) served as negative experimental controls. As a positive control, the stimulatory effects of recombinant bone morphogenetic protein-2 (BMP-2) at 500 ng/mL (InductOs, Dibtormin Alfa, Pfizer, Berlin, Germany) were measured at day 3. The application of BMP-2 resulted in a significant regulation of the target genes at the osteoblast region (Figure 2).

2.3. Real-Time Quantitative Polymerase Chain Reaction (qPCR). A RNeasy Mini Extraction Kit (Qiagen, Hilden,

TABLE 1: Primer sequences of target and reference genes.

Target gene	Product size (base pairs)	Annealing temperature (°C)	Sequence
<i>Actb</i>	200	66.5°C 66.3°C	Forward: 5' CTCTGGCTCCTAGCACCATGAAGA 3' Reverse: 5' GTAAAACGCAGCTCAGTAACAGTCCG 3'
<i>Alpl</i>	96	61.3°C 60.0°C	Forward: 5' GGCCAGCTACACCACAACA 3' Reverse: 5' CTGAGCGTTGGTGTATATGTCTT 3'
<i>Bglap</i>	102	n.a.	Qiagen (QuantiTect Primer Assay KIT BGLAP) Cat. number: QT00259406 (commercial product, no sequence available)
<i>Fmod</i>	145	62.7°C 62.2°C	Forward: 5' AGCAGTCCACCTACTACGACC 3' Reverse: 5' CAGTCGCATTCTTGGGGACA 3'
<i>Hprt</i>	173	67.1°C 66.4°C	Forward: 5' GAGGAGTCCTGTTGATGTTGCCAG 3' Reverse: 5' GGCTGGCCTATAGGCTCATAGTGC 3'
<i>Runx2</i>	207	60.3°C 60.8°C	Forward: 5' CCAACCGAGTCATTTAAGGCT 3' Reverse: 5' GCTCACGTCGCTCATCTTG 3'

Germany) was used to extract the RNA. Complementary DNA (cDNA) synthesis was performed in a FlexCycler thermal cycler (Analytik-Jena, Jena, Germany) using the iScript cDNA synthesis kit (Bio-Rad, Munich, Germany) according to the manufacturer's instructions. Standards were prepared by a tenfold dilution series between 1 and 1×10^{-5} . cDNA was stored at -20°C .

For qPCR, the SsoFast EvaGreen Supermix (Bio-Rad) and 1 μg of cDNA were processed in a Bio-Rad C1000 ThermoCycler running the CFX96 Real-Time System. Cycling conditions were 30 sec at 95°C , 40 cycles of 5 sec at 95°C , and 10 sec at 60°C . Finally, a melt-curve analysis with 0.5°C increments every 5 sec from 65°C to 95°C was performed.

The target genes were *Alpl* (alkaline phosphatase), *Bglap* (bone gamma-carboxyglutamate (gla) protein or osteocalcin), *Fmod* (fibromodulin), and *Runx2* (runt-related transcription factor 2); reference genes were *Actb* (actin beta) and *Hprt* (hypoxanthine guanine phosphoribosyl transferase). Primers were obtained from Qiagen and Sigma-Aldrich (Table 1). The primer covered at least one exon-intron junction and the negative first-deviation plots of the melting curve revealed specificity. Target gene expression was assessed using CFX Manager 3.1 software (Bio-Rad) and normalized to the reference genes.

2.4. Real-Time Cell Viability Analysis. To measure the influence of ibuprofen and parecoxib on the viability of MC3T3-E1 and 3T3 cells, the xCELLigence Real-Time Cell Analyzer (Roche Applied Science, Mannheim, Germany) and RTCA 1.2.5 software were employed according to the manufacturer's instructions. Briefly, 5,000 cells were seeded per well and incubated for 24 h (3T3) or 48 h (MC3T3) under standard conditions. Next, the medium was changed and cells were exposed to final concentrations of ibuprofen or parecoxib of 0 μM , 5 μM , 10 μM , 25 μM , 50 μM , or 100 μM . Controls were treated with either NaCl (36.02 μM) or DMSO (520 μM). The experiment was performed over 100 h at 37°C in a humidified atmosphere of air and 5% CO_2 . The cell index was acquired automatically every 15 min.

2.5. Microscopic Analysis of Proliferation and Migration at the Interface Region. To measure proliferation and migration at the interface region, the established coculture model was performed on sterile object slides (Gerhard Menzel, Braunschweig, Germany) as outlined above. The divider was removed 24 h after seeding and cultures were stimulated with LPS (1 ng/ μL) over 4 h. Next, cells were exposed to ibuprofen (100 μM) or parecoxib (12.63 μM); DMSO (520 μM) and NaCl (36.02 μM) treated cultures served as controls. The experiment was terminated at day 0, 3, or 7. Object slides were rinsed with PBS and cells were fixed for 15 min in 4% formalin. Next, slides were carefully washed with PBS, and a hematoxylin and eosin stain was performed. Slides were observed and photographed with a Leica DM LB microscope (Leica Mikrosysteme Vertrieb, Wetzlar, Germany). Quantification of combined migration and proliferation was performed by counting all visible cells in one-quarter of a visual field (at 20x magnification) of the osteoblast, interface, and fibroblast regions. For each experimental condition, slides of five independent cultures were analyzed.

2.6. Statistical Analysis. Statistical analysis was undertaken using SPSS for Mac, version 22 (SPSS, Chicago, IL, USA). All datasets were tested for normality with chi-square analysis. Groups were compared by employing one-way analysis of variance with Dunnett's multiple comparison. Statistical significance was set at $P < 0.05$. Graphs were plotted using Microsoft Excel for Mac, version 14.1.0 (Microsoft, Redmond, WA, USA).

3. Results and Discussion

3.1. Dose-Dependent Effects of Ibuprofen and Parecoxib on Cell Viability. The dose-dependent effects of ibuprofen and parecoxib on the viability of cultured MC3T3-E1 and 3T3 cells are shown in Figure 2. Ibuprofen provoked a dose-dependent reduction in the viability of MC3T3 cells from 48 h onwards when compared with untreated controls (Figure 3(a)), but there was no apparent effect on 3T3 cells (Figure 3(b)).

FIGURE 3: (a)–(d) Effects of ibuprofen and parecoxib on viability of cultured MC3T3-E1 (preosteoblast) and 3T3 (fibroblast) cells. Real-time cell viability was analyzed following the exposure to ibuprofen or parecoxib at concentrations of 0 μ M, 5 μ M, 10 μ M, 25 μ M, 50 μ M, or 100 μ M by xCELLigence over 100 h.

In contrast, parecoxib led to a significantly reduced cell viability of 3T3 cultures (Figure 3(d)), but no dose-dependent impairment of cell viability in MC3T3 cells (Figure 3(c)).

3.2. Effects of Ibuprofen and Parecoxib on Gene Expression at the Osteoblast, Interface, and Fibroblast Regions during Bone-Tendon Integration In Vitro. The region-specific effects of ibuprofen and parecoxib treatment on the expression of *Alpl*, *Bglap*, *Fmod*, and *Runx2* in LPS-stimulated and unstimulated cultures were analyzed by qPCR at 24, 48, and 72 h. Unstimulated cocultures served as controls. Isolated LPS-exposure led to significantly decreased rates of *Alpl* expression at all regions (Figures 4(a) and 4(e)), while *Bglap*, *Fmod*, and

Runx2 showed no definite regulation by LPS. Ibuprofen treatment led to reduced *Alpl* expression at the osteoblast and interface regions of LPS-treated and -untreated cultures, while no distinct regulation was noted at the fibroblast region (Figure 4(a)). Parecoxib reduced *Alpl* expression in all three regions (Figure 4(e)). *Bglap* expression was significantly downregulated by ibuprofen in LPS-untreated cultures at the interface and fibroblast regions, while expression in LPS-stimulated cells was increased significantly by ibuprofen at the interface and fibroblast regions (Figure 4(b)). Although there were significant increases in *Bglap* expression in the LPS-stimulated cultures following parecoxib treatment, a nonsignificant trend towards a decrease was also noted in

FIGURE 4: Continued.

FIGURE 4: (a)–(h) Effects of ibuprofen and parecoxib on gene expression at the osteoblast, interface, and fibroblast regions during bone-tendon integration *in vitro*. *Alpl*: alkaline phosphatase; *Bglap*: bone gamma-carboxyglutamate protein; *Fmod*: fibromodulin; LPS: lipopolysaccharide; *Runx2*: runt-related transcription factor 2. *P* values are provided as follows: * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

FIGURE 5: Microscopic morphology of the osteoblast, interface, and fibroblast regions during bone-tendon healing *in vitro*. Seven days following exposure to ibuprofen or parecoxib, murine cocultures were stained with hematoxylin and eosin, and representative regions were observed and photographed (20x magnification). *P* values are provided as follows: * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

unstimulated cultures (Figure 4(f)). There was no consistent regulation of *Fmod* by ibuprofen (Figure 4(c)), while parecoxib resulted in decreased *Fmod* expression (Figure 4(g)). *Runx2* expression was downregulated by ibuprofen and parecoxib at all three regions (Figures 4(d) and 4(h)).

3.3. Effects of Ibuprofen and Parecoxib on the Microscopic Morphology and Outgrowth of the Interface Region during Bone-Tendon Integration In Vitro. Histological growth patterns of MC3T3-E1 and 3T3 cells at the osteoblast interface

and fibroblast regions at day 7 are depicted in Figure 5. The quantitative analysis of cell outgrowth (combined proliferation and migration) revealed no inhibitory effects by ibuprofen in unstimulated cultures at the interface or fibroblast regions (Figure 6(a)), whereas the cell count was significantly increased in the osteoblast region following exposure to ibuprofen ($P < 0.001$, Figure 6(a)). However, in LPS-stimulated cocultures, ibuprofen treatment resulted in a significant decrease in the number of detectable cells at the osteoblast region ($P < 0.05$) and a trend towards reductions

FIGURE 6: (a)–(c) Effects of ibuprofen and parecoxib on region-specific cellular outgrowth during bone-tendon healing *in vitro*. DMSO: dimethyl sulfoxide; LPS: lipopolysaccharide; NaCl: sodium chloride. *P* values are provided as follows: **P* < 0.05, ***P* < 0.01, and ****P* < 0.001.

at the interface and fibroblast regions. These results were mirrored following exposure to parecoxib (Figure 6(b)), where unstimulated cultures showed increased cellular outgrowth at the osteoblast region, and inhibitory effects were noted at all three regions following LPS-stimulation.

3.4. Assessment of Findings. Ibuprofen, parecoxib, and other NSAIDs are a key part of many postoperative analgesic regimes following musculoskeletal surgery [11]. While the development of COX-2 specific drugs aimed to improve the efficacy and safety of NSAIDs, their superiority over conventional nonselective COX inhibitors remains a matter of substantial controversy [12].

Induction of COX-2 and its biochemical product prostaglandin H₂ is an important part of the healing process in musculoskeletal tissues [13], including bone [13] and tendon [14]. In musculoskeletal tissue, COX-2 is involved in a multitude of complex biological processes, including the recruitment and activity of proinflammatory cells and the formation and maturation of restored tissue [15]. We used a highly controlled *in vitro* model to investigate the influence of COX inhibition on bone-tendon integration. While we found marked suppression of markers of bone and noncalcified extracellular matrix formation following ibuprofen and parecoxib exposure, the published literature on the role of COX inhibition on bone-tendon healing remains controversial [16]. Several studies have reported beneficial effects of anti-inflammatory measures on tendon healing. Oak and colleagues showed that inhibition of 5-lipoxygenase, COX-1, and COX-2 led to improved tendon healing [17], and Krivic and colleagues reported that tendon healing was enhanced by an immunosuppressive protocol involving the peptide BPC 157 and systemic methylprednisolone *in vivo* [18]. Further evidence indicating the advantageous effects of limiting inflammation in injured tendons was provided by the study of McCarrel and colleagues, who reported that leukocyte-reduced platelet-rich plasma was superior to standard platelet-rich plasma in an *in vitro* model [19].

In contrast, Kocaoglu and colleagues reported that immunosuppression with mitomycin-C had no effect on the tensile load required to rupture repaired tendons, even though microscopic signs of inflammation were significantly decreased [20]. Although another group found that specific selective COX-2 inhibition with celecoxib did not influence tendon healing [21], it has been reported that systemic ibuprofen administered in the first postoperative week has detrimental effects on tendon healing in a rat supraspinatus tendon repair model (although ibuprofen administered only in the second postoperative week did not) [22].

The role of COX inhibition on bone formation and fracture healing has been studied extensively [23], but there is still significant controversy about the specific effects of selective COX-2 and nonselective COX inhibition. The majority of published studies reported reduced rates of callus formation and delayed fracture healing following treatment with selective and nonselective COX inhibitors [24–31]. Interestingly, Utvåg's group found that both selective COX-2 inhibition and nonselective COX inhibition administered for only the first

7 days after the fracture did not significantly influence bone regeneration and concluded that short-term treatment with an NSAID might not impair fracture healing [32].

While O'Connor and colleagues reported that treatment with the selective COX-2 inhibitor rofecoxib resulted in less effective fracture healing compared with ibuprofen [30], Gerstenfeld et al. found that parecoxib had only a minimal effect on healing, even at doses that are known to fully inhibit prostaglandin production [25]. The latter authors' conclusion that a selective COX-2 inhibitor has less effect on fracture repair compared with nonselective NSAIDs has been challenged, as the pharmacokinetic characteristics of the drugs used in the study can be unpredictable [33]. While we found some drug-specific differences, both selective and nonselective COX inhibition led to significant impairment of *in vitro* bone-tendon healing.

A relevant limitation of the majority of the previously published *in vitro* studies is the lack of an adequate proinflammatory stimulus in the experimental setup. For the present study LPS was administered to induce inflammatory signaling in both cell lines, thus simulating the early postoperative situation following ACL reconstruction. LPS has been reported to be a proinflammatory stimulus in MC3T3-E1 cells by Guo et al. [34]. The authors noted an LPS triggered activation of the JNK pathway, eventually leading to an inhibition of osteoblast differentiation and programmed cell death. In their classic paper, Arakawa et al. reported on the effects of LPS on the expression of the prostaglandin receptor gene EP4 in 3T3 cells [35], underlining the proinflammatory effect of LPS in this murine mesenchymal cell line.

3.5. Study Limitations. While using an established *in vitro* coculture model enabled highly standardized and reproducible experiments to be performed, the complexity of bone-tendon healing, including the involvement of other cell types in a complex three-dimensional extracellular matrix, could not be reproduced. Furthermore, no biomechanical influences on the model were assessed. Another potential limitation could be the use of established murine cell lines; however, the rationale for using murine cell lines instead of human cell cultures was primarily the excellent characterization of their molecular background by previous studies. Next, a wide range of molecular tools have been constructed for murine cells, enabling complex experimental approaches for future studies. Furthermore, MC3T3-E1 and 3T3 cells are globally available, thus improving the reproducibility of our data.

Next, we measured gene expression but did not assay protein concentrations. Furthermore, the expression analysis was limited to four genes serving as surrogate parameters of osteointegration (*Alpl*, *Bglap*, and *Runx2*) and extracellular matrix formation and maturation (*Fmod*). The role of *Alpl*, *Bglap*, and *Runx2* in osteoblast differentiation [36] has been studied extensively, and their importance for bone-tendon integration has been underlined previously [37, 38]. Fibromodulin (*Fmod*) has been identified to be a key participant in the organization of extracellular matrix by interacting with collagen fibrils and has been described as an important

structural component of tendon and cartilage tissue [39]. However, the authors are aware that the analysis of the effects of the COX inhibition on noncalcified extracellular matrix formation and maturation is limited and should be further dissected by future studies employing long-term cultured tendon specimens [37] and animal models [7].

Another drawback of the study is the limitation on two COX inhibitors, that is, ibuprofen and parecoxib. However, both ibuprofen and parecoxib are widely used as anti-inflammatory drugs and have become the postoperative therapeutic standard in orthopedic practice. Thus, the present study aimed to transfer the clinical issue of a potential interference between ibuprofen or parecoxib and bone-tendon healing to the highly controlled experimental setup of a cell based *in vitro* study.

Finally, the induction or inhibition of COX-1 and COX-2 was not specifically measured.

4. Conclusions

Nonselective COX inhibition and the specific inhibition of COX-2 resulted in region-specific reductions in expression of markers of calcification and extracellular matrix synthesis *in vitro*. Furthermore, parameters indicative of cell viability, proliferation, and migration were suppressed by COX inhibition. As NSAIDs are in widespread clinical use to manage pain after ACL surgery, further *in vitro* and *in vivo* studies examining the biologic and biomechanical effects of COX inhibition are needed.

Conflict of Interests

The authors have no relevant financial relationships to disclose and declare no potential conflict of interests.

Authors' Contribution

Tim Schwarting, Sebastian Pretzsch, and Philipp Lechler designed the study. Sebastian Pretzsch performed the experiments. Tim Schwarting and Philipp Lechler performed statistical analysis. Tim Schwarting, Sebastian Pretzsch, Steffen Ruchholtz, and Philipp Lechler participated in data interpretation. Tim Schwarting and Philipp Lechler wrote the paper. All authors read and approved the final draft of the paper.

Acknowledgments

The study was funded by the University Hospitals of Giessen and Marburg, according to §2 passage 3 (research funding) of the interhospital cooperation contract. The authors would like to thank Mrs. Claudia Krappen (Freistil Design, Geldern, Germany) for her help with graphic design and Mrs. Pia Janssen for her technical assistance. Furthermore, they are grateful to Mr. Dano Schenk and Mr. Michael Benölken for their efforts establishing the methodological setup.

References

- [1] L.-P. Granan, R. Bahr, K. Steindal, O. Furnes, and L. Engebretsen, "Development of a national cruciate ligament surgery registry: the Norwegian National Knee Ligament Registry," *The American Journal of Sports Medicine*, vol. 36, no. 2, pp. 308–315, 2008.
- [2] L. C. S. Mihata, A. I. Beutler, and B. P. Boden, "Comparing the incidence of anterior cruciate ligament injury in collegiate lacrosse, soccer, and basketball players: implications for anterior cruciate ligament mechanism and prevention," *American Journal of Sports Medicine*, vol. 34, no. 6, pp. 899–904, 2006.
- [3] D. J. Biau, S. Katsahian, J. Kartus et al., "Patellar tendon versus hamstring tendon autografts for reconstructing the anterior cruciate ligament: a meta-analysis based on individual patient data," *The American Journal of Sports Medicine*, vol. 37, no. 12, pp. 2470–2478, 2009.
- [4] C. B. Frank and D. W. Jackson, "The science of reconstruction of the anterior cruciate ligament," *The Journal of Bone & Joint Surgery—American Volume*, vol. 79, no. 10, pp. 1556–1576, 1997.
- [5] M. A. Kessler, H. Behrend, S. Henz, G. Stutz, A. Rukavina, and M. S. Kuster, "Function, osteoarthritis and activity after ACL-rupture: 11 Years follow-up results of conservative versus reconstructive treatment," *Knee Surgery, Sports Traumatology, Arthroscopy*, vol. 16, no. 5, pp. 442–448, 2008.
- [6] B. E. Øiestad, L. Engebretsen, K. Storheim, and M. A. Risberg, "Knee osteoarthritis after anterior cruciate ligament injury: a systematic review," *The American Journal of Sports Medicine*, vol. 37, no. 7, pp. 1434–1443, 2009.
- [7] V. Lovric, D. Chen, Y. Yu, R. A. Oliver, F. Genin, and W. R. Walsh, "Effects of demineralized bone matrix on tendon-bone healing in an intra-articular rodent model," *The American Journal of Sports Medicine*, vol. 40, no. 10, pp. 2365–2374, 2012.
- [8] S. Dimmen, L. Nordsletten, L. Engebretsen, H. Steen, and J. E. Madsen, "The effect of parecoxib and indometacin on tendon-to-bone healing in a bone tunnel: an experimental study in rats," *The Journal of Bone and Joint Surgery—British Volume*, vol. 91, no. 2, pp. 259–263, 2009.
- [9] Z. A. Radi and N. K. Khan, "Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing," *Inflammation Research*, vol. 54, no. 9, pp. 358–366, 2005.
- [10] I.-N. E. Wang, J. Shan, R. Choi et al., "Role of osteoblast-fibroblast interactions in the formation of the ligament-to-bone interface," *Journal of Orthopaedic Research*, vol. 25, no. 12, pp. 1609–1620, 2007.
- [11] E. F. Ekman and L. A. Koman, "Acute pain following musculoskeletal injuries and orthopaedic surgery: mechanisms and management," *Instructional Course Lectures*, vol. 54, pp. 21–33, 2005.
- [12] J. A. Katz, "COX-2 inhibition: what we learned—a controversial update on safety data," *Pain Medicine*, vol. 14, supplement 1, pp. S29–S34, 2013.
- [13] C. Huang, M. Xue, H. Chen et al., "The spatiotemporal role of COX-2 in osteogenic and chondrogenic differentiation of periosteum-derived mesenchymal progenitors in fracture repair," *PLoS ONE*, vol. 9, no. 7, Article ID e100079, 2014.
- [14] G. Schulze-Tanzil, O. Al-Sadi, E. Wiegand et al., "The role of pro-inflammatory and immunoregulatory cytokines in tendon healing and rupture: new insights," *Scandinavian Journal of Medicine & Science in Sports*, vol. 21, no. 3, pp. 337–351, 2011.

- [15] J. P. O'Connor, M. B. Manigrasso, B. D. Kim, and S. Subramanian, "Fracture healing and lipid mediators," *BoneKEy Reports*, vol. 3, article 517, 2014.
- [16] B. Su and J. P. O'Connor, "NSAID therapy effects on healing of bone, tendon, and the enthesis," *Journal of Applied Physiology*, vol. 115, no. 6, pp. 892–899, 2013.
- [17] N. R. Oak, J. P. Gumucio, M. D. Flood et al., "Inhibition of 5-LOX, COX-1, and COX-2 increases tendon healing and reduces muscle fibrosis and lipid accumulation after rotator cuff repair," *The American Journal of Sports Medicine*, vol. 42, no. 12, pp. 2860–2868, 2014.
- [18] A. Krivic, M. Majerovic, I. Jelic, S. Seiwerth, and P. Sikiric, "Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone," *Inflammation Research*, vol. 57, no. 5, pp. 205–210, 2008.
- [19] T. M. McCarrel, T. Minas, and L. A. Fortier, "Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy," *The Journal of Bone & Joint Surgery—American Volume*, vol. 94, no. 19, article e143, pp. 141–148, 2012.
- [20] B. Kocaoglu, I. Agir, U. Nalbantoglu, M. Karahan, and M. Türkmen, "Effect of mitomycin-C on post-operative adhesions in tendon surgery: an experimental study in rats," *The Journal of Bone and Joint Surgery—British Volume*, vol. 92, no. 6, pp. 889–893, 2010.
- [21] O. Dolkart, T. Liron, O. Chechik et al., "Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study," *The American Journal of Sports Medicine*, vol. 42, no. 12, pp. 2869–2876, 2014.
- [22] B. K. Connizzo, S. M. Yannascoli, J. J. Tucker et al., "The detrimental effects of systemic Ibuprofen delivery on tendon healing are time-dependent," *Clinical Orthopaedics and Related Research*, vol. 472, no. 8, pp. 2433–2439, 2014.
- [23] P. Geusens, P. J. Emans, J. J. A. de Jong, and J. van den Bergh, "NSAIDs and fracture healing," *Current Opinion in Rheumatology*, vol. 25, no. 4, pp. 524–531, 2013.
- [24] K. M. Brown, M. M. Saunders, T. Kirsch, H. J. Donahue, and J. S. Reid, "Effect of COX-2-specific inhibition on fracture-healing in the rat femur," *The Journal of Bone and Joint Surgery—American Volume*, vol. 86, no. 1, pp. 116–123, 2004.
- [25] L. C. Gerstenfeld, M. Thiede, K. Siebert et al., "Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs," *Journal of Orthopaedic Research*, vol. 21, no. 4, pp. 670–675, 2003.
- [26] L. S. Gregory and M. R. Forwood, "Cyclooxygenase-2 inhibition delays the attainment of peak woven bone formation following four-point bending in the rat," *Calcified Tissue International*, vol. 80, no. 3, pp. 176–183, 2007.
- [27] D. J. Hak, K. S. Schulz, B. Khoie, and S. J. Hazelwood, "The effect of Cox-2 specific inhibition on direct fracture healing in the rabbit tibia," *Journal of Orthopaedic Science*, vol. 16, no. 1, pp. 93–98, 2011.
- [28] M. Kellinsalmi, V. Parikka, J. Risteli et al., "Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro," *European Journal of Pharmacology*, vol. 572, no. 2–3, pp. 102–110, 2007.
- [29] L. J. Kidd, N. R. Cowling, A. C. Wu, W. L. Kelly, and M. R. Forwood, "Selective and non-selective cyclooxygenase inhibitors delay stress fracture healing in the rat ulna," *Journal of Orthopaedic Research*, vol. 31, no. 2, pp. 235–242, 2013.
- [30] J. P. O'Connor, J. T. Capo, V. Tan et al., "A comparison of the effects of ibuprofen and rofecoxib on rabbit fibula osteotomy healing," *Acta Orthopaedica*, vol. 80, no. 5, pp. 597–605, 2009.
- [31] A. M. Simon and J. P. O'Connor, "Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing," *The Journal of Bone and Joint Surgery—American Volume*, vol. 89, no. 3, pp. 500–511, 2007.
- [32] S. E. Utvåg, O. M. Fuskevåg, H. Shegarfi, and O. Reikerås, "Short-term treatment with COX-2 inhibitors does not impair fracture healing," *Journal of Investigative Surgery*, vol. 23, no. 5, pp. 257–261, 2010.
- [33] P. Aspenberg and T. A. Einhorn, "Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs," *Journal of Orthopaedic Research*, vol. 22, no. 3, pp. 684–685, 2004.
- [34] C. Guo, L. Yuan, J.-G. Wang et al., "Lipopolysaccharide (LPS) induces the apoptosis and inhibits osteoblast differentiation through JNK pathway in MC3T3-E1 cells," *Inflammation*, vol. 37, no. 2, pp. 621–631, 2014.
- [35] T. Arakawa, O. Laneuville, C. A. Miller et al., "Prostanoid receptors of murine NIH 3T3 and raw 264.7 cells: structure and expression of the murine prostaglandin EP4 receptor gene," *The Journal of Biological Chemistry*, vol. 271, no. 47, pp. 29569–29575, 1996.
- [36] J. Sodek, J. Chen, T. Nagata et al., "Regulation of osteopontin expression in osteoblasts," *Annals of the New York Academy of Sciences*, vol. 760, pp. 223–241, 1995.
- [37] T. Schwarting, P. Lechler, J. Struwer et al., "Bone morphogenetic protein 7 (BMP-7) influences tendon-bone integration in vitro," *PLOS ONE*, vol. 10, no. 2, Article ID e0116833, 2015.
- [38] T. Schwarting, M. Benölken, S. Ruchholtz, M. Frink, and P. Lechler, "Bone morphogenetic protein-7 enhances bone-tendon integration in a murine in vitro co-culture model," *International Orthopaedics*, vol. 39, no. 4, pp. 799–805, 2015.
- [39] F. Gori, E. Schipani, and M. B. Demay, "Fibromodulin is expressed by both chondrocytes and osteoblasts during fetal bone development," *Journal of Cellular Biochemistry*, vol. 82, no. 1, pp. 46–57, 2001.